Ironwood Pharmaceuticals. has filed a patent for peptides and compositions that can be used to treat various gastrointestinal disorders and conditions, such as irritable bowel syndrome, Crohn’s disease, and constipation. The patent claims a specific peptide sequence that activates the guanylate cyclase C receptor. GlobalData’s report on Ironwood Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ironwood Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Ironwood Pharmaceuticals's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Peptide for treating gastrointestinal disorders
A recently filed patent (Publication Number: US20230272007A1) describes a peptide or a pharmaceutically acceptable salt thereof that has potential therapeutic applications in treating gastrointestinal disorders. The peptide has a specific amino acid sequence and structure, with the a-amine of the Cys1 amino acid deaminated. The patent claims cover various aspects of the peptide, including its composition, isolation, purification, and use in pharmaceutical compositions.
The peptide described in the patent activates the guanylate cyclase C receptor, which is involved in regulating intestinal motility. This suggests that the peptide may be effective in treating gastrointestinal disorders such as irritable bowel syndrome (IBS), constipation, functional gastrointestinal disorders, gastroesophageal reflux disease, and others.
The patent also specifies that the peptide consists of 30 or fewer amino acids, making it a relatively small molecule. Additionally, the peptide may be isolated or purified, indicating that it can be obtained in a highly concentrated and pure form for pharmaceutical use.
The patent further describes pharmaceutical compositions that include the peptide or its pharmaceutically acceptable salt, either alone or in combination with other peptides or therapeutic agents. These compositions may also contain additional agents such as cations (e.g., magnesium, calcium, zinc) or sterically hindered primary amines, which can enhance the therapeutic effects of the peptide.
The pharmaceutical compositions may be formulated as capsules or tablets, and each dosage unit may contain a specific amount of the peptide, ranging from 5 µg to 1 mg of linaclotide. Linaclotide, a specific peptide mentioned in the patent, can be included in the compositions along with the described peptide.
The patent also discloses methods for treating gastrointestinal disorders by administering the pharmaceutical composition. These disorders include constipation, IBS, dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease. The patent also claims methods for increasing intestinal motility and guanylate cyclase C receptor activity using the peptide.
Overall, this patent describes a peptide with potential therapeutic applications in treating various gastrointestinal disorders. The peptide's specific amino acid sequence, structure, and ability to activate the guanylate cyclase C receptor make it a promising candidate for further development and clinical evaluation.
To know more about GlobalData’s detailed insights on Ironwood Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
